[go: up one dir, main page]

ATE515700T1 - Blutgruppenantigene verschiedener typen für diagnostische und therapeutische anwendungen - Google Patents

Blutgruppenantigene verschiedener typen für diagnostische und therapeutische anwendungen

Info

Publication number
ATE515700T1
ATE515700T1 AT07804873T AT07804873T ATE515700T1 AT E515700 T1 ATE515700 T1 AT E515700T1 AT 07804873 T AT07804873 T AT 07804873T AT 07804873 T AT07804873 T AT 07804873T AT E515700 T1 ATE515700 T1 AT E515700T1
Authority
AT
Austria
Prior art keywords
diagnostic
different types
therapeutic applications
blood group
group antigens
Prior art date
Application number
AT07804873T
Other languages
English (en)
Inventor
Jan Holgersson
Jining Liu
Linda Bjornstrom
Per Grufman
Original Assignee
Absorber Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Absorber Ab filed Critical Absorber Ab
Application granted granted Critical
Publication of ATE515700T1 publication Critical patent/ATE515700T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4725Mucins, e.g. human intestinal mucin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • G01N2800/245Transplantation related diseases, e.g. graft versus host disease
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125Digestion or removing interfering materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07804873T 2006-03-23 2007-03-23 Blutgruppenantigene verschiedener typen für diagnostische und therapeutische anwendungen ATE515700T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78570006P 2006-03-23 2006-03-23
PCT/IB2007/002530 WO2007135571A2 (en) 2006-03-23 2007-03-23 Blood group antigens of different types for diagnostic and therapeutic applications

Publications (1)

Publication Number Publication Date
ATE515700T1 true ATE515700T1 (de) 2011-07-15

Family

ID=38617489

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07804873T ATE515700T1 (de) 2006-03-23 2007-03-23 Blutgruppenantigene verschiedener typen für diagnostische und therapeutische anwendungen

Country Status (14)

Country Link
US (2) US7897328B2 (de)
EP (3) EP2010920B1 (de)
JP (2) JP2009536150A (de)
CN (1) CN101405603A (de)
AT (1) ATE515700T1 (de)
AU (1) AU2007252926A1 (de)
BR (1) BRPI0709102A2 (de)
CA (1) CA2643991A1 (de)
ES (1) ES2371039T3 (de)
IL (2) IL213523A0 (de)
MX (1) MX2008012167A (de)
NZ (1) NZ572194A (de)
SG (2) SG171598A1 (de)
WO (1) WO2007135571A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0706558D0 (en) * 2007-04-03 2007-05-09 Common Services Agency For The Diagnostic assay
EP2734841B1 (de) 2011-07-20 2017-07-05 University Of Washington Through Its Center For Commercialization Photonische blutgruppenbestimmung
AU2012304181C1 (en) * 2011-08-30 2017-04-27 The Governors Of The University Of Alberta Method and system for ABO antibody detection and characterization
EP2771087A4 (de) * 2011-10-28 2015-06-10 Glycorex Transplantation Ab Verfahren zur extrakorporalen ausscheidung von einem oder mehreren bestandteilen aus blut
US10031138B2 (en) 2012-01-20 2018-07-24 University Of Washington Through Its Center For Commercialization Hierarchical films having ultra low fouling and high recognition element loading properties
CN103926415B (zh) * 2014-03-24 2015-11-25 上海市血液中心 人血液中血型抗体联合快速检测体系
EP3062109A1 (de) * 2015-02-25 2016-08-31 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Antikörpererkennungsverfahren und -system
EP3341738A4 (de) 2015-08-24 2019-02-27 University of Cincinnati Verfahren und zusammensetzungen zum nachweis von fc-rezeptorbindender aktivität von antikörpern
US10697983B2 (en) * 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies
BR112020016548A2 (pt) 2018-02-16 2020-12-22 Diagast Dispositivo de diagnóstico in vitro, uso do mesmo e métodos in vitro
CN108375572A (zh) * 2018-02-26 2018-08-07 深圳市生强科技有限公司 基于化学发光法的检测方法及装置
CN111257556A (zh) * 2018-11-30 2020-06-09 深圳市帝迈生物技术有限公司 一种免疫分析仪及样本分析方法
EP4245764A1 (de) 2022-03-18 2023-09-20 RemAb Therapeutics SL Neue kohlenhydratderivate als mimetika der antigene der blutgruppen a und b
CN115343485B (zh) * 2022-10-18 2023-01-06 天津德祥生物技术股份有限公司 血型抗原三糖偶联物在血型抗体检测中的应用
CN117269517B (zh) * 2022-10-18 2024-04-16 天津德祥生物技术股份有限公司 一种血型抗原三糖b类似物蛋白偶联物在血型抗体检测中的应用
AU2023382172A1 (en) * 2022-11-15 2025-06-26 The Governors Of The University Of Alberta Multiplex abo antibody assay and method

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US4603209A (en) 1984-09-07 1986-07-29 The Regents Of The University Of California Fluorescent indicator dyes for calcium ions
US4710761A (en) 1985-07-09 1987-12-01 American Telephone And Telegraph Company, At&T Bell Laboratories Window border generation in a bitmapped graphics workstation
US4714763A (en) * 1985-07-11 1987-12-22 Viomedics Inc. Novel oxazine-ureas and thiazine urea chromophors as fluorescent labels
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US5569587A (en) 1986-04-18 1996-10-29 Carnegie Mellon University Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US4810636A (en) * 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
US4857639A (en) * 1987-01-12 1989-08-15 The Biomembrane Institute A-associated H-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US4849362A (en) 1988-05-19 1989-07-18 Smithkline Beckman Corporation Fluorescent intracellular calcium indicators
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US4981977A (en) 1989-06-09 1991-01-01 Carnegie-Mellon University Intermediate for and fluorescent cyanine dyes containing carboxylic acid groups
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5501980A (en) * 1994-05-20 1996-03-26 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5459276A (en) 1994-05-20 1995-10-17 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators for heavy metals
WO1991017440A1 (en) * 1990-05-07 1991-11-14 Immunomedics, Inc. Improved method for radiolabeling monovalent antibody fragments
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5451343A (en) 1991-05-20 1995-09-19 Spectra Group Limited, Inc. Fluorone and pyronin y derivatives
US5187288A (en) * 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5242805A (en) 1991-08-23 1993-09-07 Molecular Probes, Inc. Long wavelength lipophilic fluorogenic glycosidase substrates
US5808044A (en) 1993-01-22 1998-09-15 Pharmacia Biotech Inc. Indocarbocyanine and benzindocarbocyanine phosphoramidites
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US5420368A (en) * 1994-06-29 1995-05-30 E. I. Du Pont De Nemours And Company Production CF3 CH2 CF3 and/or CF3 CH═CF2 by the conversion of fluorinated ethers
US6127134A (en) 1995-04-20 2000-10-03 Carnegie Mellon University Difference gel electrophoresis using matched multiple dyes
US6008373A (en) * 1995-06-07 1999-12-28 Carnegie Mellon University Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
US6004536A (en) 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
US6162931A (en) 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
DE69706417T2 (de) 1996-04-19 2002-06-27 Amersham Pharmacia Biotech Uk Ltd., Little Chalfont Quadratfarbstoffe und deren verwendung in einem fluorescenzsequenzierungsverfahren
US5776711A (en) * 1996-11-12 1998-07-07 The Regents Of The University Of California Simultaneous human ABO and RH(D) blood typing or antibody screening by flow cytometry
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US6686457B1 (en) * 1996-12-23 2004-02-03 Kurt Nilsson Material
US5877310A (en) 1997-04-25 1999-03-02 Carnegie Mellon University Glycoconjugated fluorescent labeling reagents
US5948627A (en) * 1997-05-30 1999-09-07 One Lambda Immunobead flow cytometric detection of anti-HLA panel-reactive antibody
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6133445A (en) * 1997-12-17 2000-10-17 Carnegie Mellon University Rigidized trimethine cyanine dyes
EP1078023B1 (de) 1998-04-08 2011-01-05 Corporation Luminex Lumineszierende verbindungen
US6002003A (en) 1998-04-14 1999-12-14 Beckman Instruments, Inc. Cyanine dye activating group with improved coupling selectivity
JP3983404B2 (ja) * 1999-01-13 2007-09-26 本田技研工業株式会社 レーダ搭載車両用ゲート
US6664047B1 (en) * 1999-04-30 2003-12-16 Molecular Probes, Inc. Aza-benzazolium containing cyanine dyes
EP1065250B1 (de) 1999-07-02 2004-12-08 Visen Medical, Inc. Fluorescierende Cyaninlabels mit einem Sulphamidobrückenglied
DE60020584T2 (de) 1999-09-20 2006-04-27 Fuji Photo Film Co., Ltd., Minami-Ashigara Verbindungen zur fluoreszenz-kennzeichnung
EP2045252B1 (de) * 2000-08-04 2013-05-01 Life Technologies Corporation Derivate aus 1,2-Dihydro-7-Hydroxychinolinen mit fusionierten Ringen
CA2423806C (en) 2000-09-29 2009-12-22 Molecular Probes, Inc. Modified carbocyanine dyes and their conjugates
WO2003010201A2 (en) * 2001-07-20 2003-02-06 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof

Also Published As

Publication number Publication date
JP2009536150A (ja) 2009-10-08
EP2010920B1 (de) 2011-07-06
US20110287556A1 (en) 2011-11-24
JP2013011626A (ja) 2013-01-17
MX2008012167A (es) 2009-01-07
IL213523A0 (en) 2011-07-31
EP2362223A2 (de) 2011-08-31
WO2007135571A3 (en) 2008-06-19
NZ572194A (en) 2012-02-24
CA2643991A1 (en) 2007-11-29
EP2362224A2 (de) 2011-08-31
EP2362224A3 (de) 2012-03-14
AU2007252926A1 (en) 2007-11-29
ES2371039T3 (es) 2011-12-26
US20070224652A1 (en) 2007-09-27
EP2362223A3 (de) 2012-03-07
BRPI0709102A2 (pt) 2011-06-28
CN101405603A (zh) 2009-04-08
IL213524A0 (en) 2011-07-31
US7897328B2 (en) 2011-03-01
SG171599A1 (en) 2011-06-29
SG171598A1 (en) 2011-06-29
EP2010920A2 (de) 2009-01-07
US8404456B2 (en) 2013-03-26
WO2007135571A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
ATE515700T1 (de) Blutgruppenantigene verschiedener typen für diagnostische und therapeutische anwendungen
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
ATE526421T1 (de) Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
DK1951759T3 (da) Anti-EGFR-antistoffer
ATE481640T1 (de) Diagnostika, drogenscreening und behandlung für krebs
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
DE602006021645D1 (de) Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
DE602005021684D1 (de) Verfahren zur herstellung von pimecrolimus
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
DE502006007526D1 (de) Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
BR112018013247A2 (pt) tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
NO20064896L (no) Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer
IL311256A (en) Methods and uses of microbiome compositions, components, or metabolites for treating neurodegenerative diseases
ATE462702T1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
ATE533783T1 (de) Potente und selektive mittlersubstanzen von cholesterolefflux
DE602004029061D1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
BRPI0607058A2 (pt) métodos para aumentar a disposição de fármaco
DE602004019569D1 (de) Verwendung von Hydrocortison zur Behandlung von Depression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties